Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775072 · ClinicalTrials.gov registry record
Genomic Profiling in Cancer Patients
A clinical trial of Solid Tumors and Hematologic Cancers, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 18
- Study locations
NCT01775072: Recruiting study of Solid Tumors and Hematologic Cancers, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01775072 is a study of Solid Tumors and Hematologic Cancers that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 200 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (29% lower). The trial reports 18 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775072, a study of Solid Tumors and Hematologic Cancers, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison. The purpose of Part B of this study is to: Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.
Primary Outcome
"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.
Conditions Studied
Interventions
- GENETIC molecular profiling of tumors
- GENETIC Clinical Germline Analysis
Study Locations (18)
New York
- Kings County Hopsital Center - Brooklyn
- Memorial Sloan Kettering Cancer Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Queens Cancer Center of Queens Hospital - Jamaica
- Metropolitan Hospital Center - New York
- Ralph Lauren Center for Cancer Care and Prevention - New York
- Memorial Sloan Kettering Cancer Center - New York
- Medisys Health Network (Data Collection Only) - Richmond Hill
- NYC Health & Hospitals /Lincoln Medical Center - The Bronx
- Memorial Sloan Kettering Nassau - Uniondale
Connecticut
- St. Vincent (Data Collection Only) - Bridgeport
- Hartford Healthcare Cancer Institute @ Hartford Hospital - Hartford
- Norwalk Hospital - Norwalk
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- Baptist Alliance MCI - Miami
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2013-01 |
| Est. Completion | 2027-01 |
What NCT01775072 shows while recruiting
NCT01775072 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which molecular profiling of tumors is the first listed.
NCT01775072 lists 18 locations in 5 states (New York, Connecticut, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01775072 about?
NCT01775072 is a clinical study titled "Genomic Profiling in Cancer Patients". The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Som...
What is the current status of trial NCT01775072?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2013-01. Estimated completion is 2027-01.
What conditions does trial NCT01775072 study?
This clinical trial studies the following conditions: Solid Tumors, Hematologic Cancers.
What interventions are being tested in trial NCT01775072?
The interventions under investigation include: molecular profiling of tumors (GENETIC), Clinical Germline Analysis (GENETIC).
Who is sponsoring clinical trial NCT01775072?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01775072 being conducted?
This trial has 18 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01775072's enrollment target sits among peer trials
200 29th of 125 higher than 97 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
RECRUITING · Phase 4
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia